IntelliPharmaCeutics International Inc. (IPCI) Analysts See $-0.07 EPS

June 13, 2018 - By Duane Lopez

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Logo

Analysts expect IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) to report $-0.07 EPS on July, 10.They anticipate $0.01 EPS change or 16.67 % from last quarter’s $-0.06 EPS. After having $-0.09 EPS previously, IntelliPharmaCeutics International Inc.’s analysts see -22.22 % EPS growth. The stock decreased 2.25% or $0.0106 during the last trading session, reaching $0.4604. About 196,581 shares traded. IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has declined 78.43% since June 13, 2017 and is downtrending. It has underperformed by 91.00% the S&P500.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Coverage

Among 2 analysts covering IntelliPharmaCeutics Intl (NASDAQ:IPCI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. IntelliPharmaCeutics Intl had 5 analyst reports since January 19, 2018 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Monday, February 12. The stock of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has “Hold” rating given on Friday, February 16 by Maxim Group. As per Monday, March 5, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) on Tuesday, May 29 with “Buy” rating.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and makes novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. The company has market cap of $19.42 million. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. It currently has negative earnings. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders.

Another recent and important IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) news was published by Seekingalpha.com which published an article titled: “FDA OKs first non-opioid treatment for opioid withdrawal” on May 16, 2018.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: